Bhana Nila
Wolters Kluwer Health Adis, Auckland, New Zealand.
Curr Opin Oncol. 2007 Jul;19(4):328-35. doi: 10.1097/01.cco.0000275309.58868.11.
(1) Neutropenia is a frequent complication of chemotherapy associated with life-threatening infections, hospitalisation, and chemotherapy dose reductions and delays.(2) Primary prophylaxis with granulocyte colony-stimulating factors has been shown to reduce the incidence and duration of neutropenia, febrile neutropenia, infections, hospitalisation and antibiotic use.(3) Recent randomised clinical trials of filgrastim, lenograstim and pegfilgrastim showed variable results across patient groups at different risks of febrile neutropenia.(4) Pegfilgrastim is at least as effective as filgrastim in the prophylaxis of chemotherapy-induced neutropenia and has improved pharmacokinetics requiring reduced administration.
(1) 中性粒细胞减少是化疗常见的并发症,与危及生命的感染、住院以及化疗剂量减少和延迟相关。(2) 已证明使用粒细胞集落刺激因子进行一级预防可降低中性粒细胞减少、发热性中性粒细胞减少、感染、住院和抗生素使用的发生率及持续时间。(3) 最近关于非格司亭、来格司亭和培非格司亭的随机临床试验表明,在不同发热性中性粒细胞减少风险的患者组中结果各异。(4) 培非格司亭在预防化疗引起的中性粒细胞减少方面至少与非格司亭一样有效,并且其药代动力学有所改善,给药次数减少。